Pilatus Biosciences Doses First Patient With Anti-CD36 Antibody PLT012 in Solid Tumors

Pilatus Biosciences has dosed the first patient in a Phase 1 clinical trial of PLT012, a humanized monoclonal antibody that blocks CD36-mediated fatty acid uptake in the tumor microenvironment. The open-label, multi-center study enrolls patients with advanced solid tumors, with expansion cohorts planned in liver cancers and tumors with liver metastases. Primary endpoints are safety, tolerability, maximum tolerated dose, and recommended Phase 2 dose, with secondary assessments of pharmacokinetics, pharmacodynamics, biomarkers, and early clinical response. The first patient was treated at Next Oncology in Houston, Texas. PLT012 holds FDA Orphan Drug Designation for hepatocellular carcinoma and intrahepatic bile duct cancer, and received Fast Track Designation for HCC in February 2026. (Source)

Pilatus, founded in 2022 from the Ludwig Institute for Cancer Research and supported by the Cancer Research Institute, describes PLT012 as a first-in-class metabolic checkpoint antibody. The company has also established a clinical trial collaboration with Roche, which is supplying atezolizumab for a combination arm evaluating PLT012 alongside anti-PD-L1 therapy in HCC. Enrolment numbers and a projected completion date were not disclosed in the announcement. No AllSci listing for this specific trial was identified at the time of writing.

Research Context

CD36 is a scavenger receptor that facilitates fatty acid uptake across multiple cell types. Within tumors, particularly in the lipid-rich liver microenvironment, CD36 activity drives metabolic reprogramming of regulatory T cells and tumor-associated macrophages, while simultaneously inducing lipid-mediated exhaustion in cytotoxic CD8+ T cells and NK cells. PLT012 is designed to interrupt this axis by blocking CD36-mediated lipid uptake, thereby depleting immunosuppressive populations and restoring effector cell function. Preclinical data published in Cancer Discovery (2025) showed that PLT012 reduced tumor growth in murine models of hepatic and subcutaneous tumors, with associated decreases in M2 macrophages and Tregs and increased CD8+ T cell infiltration. The antibody also resensitized tumors to anti-PD-1 therapy in models of liver metastasis-associated checkpoint inhibitor resistance. AllSci analysis of immunotherapy strategies in gastrointestinal carcinoma frames the metabolic immunosuppression of the liver microenvironment as a persistent barrier to durable responses with existing checkpoint blockade (AllSci).

The current standard of care for advanced HCC centers on immune checkpoint inhibitor combinations. Atezolizumab plus bevacizumab (Genentech/Roche), approved in 2020, remains a first-line option, joined by tremelimumab plus durvalumab (AstraZeneca, approved 2022) and nivolumab plus ipilimumab (Bristol Myers Squibb, approved April 2025). Tyrosine kinase inhibitors sorafenib (Bayer) and lenvatinib (Eisai) serve patients ineligible for immunotherapy, while cabozantinib (Exelixis), regorafenib (Bayer), and ramucirumab (Eli Lilly) are used after first-line progression. Despite these options, only approximately 30% of patients respond to first-line ICI regimens, and post-progression therapies offer modest survival extensions. AllSci analysis notes that multidisciplinary management remains essential given the complexity of underlying liver disease (AllSci), but no approved therapy addresses lipid-driven immune exhaustion, the mechanism PLT012 targets.

Based on available data, PLT012 appears to be the only CD36-targeting antibody in clinical development for cancer. No competing anti-CD36 molecules were identified in the AllSci clinical trials database or on clinicaltrials.gov. The broader HCC pipeline remains active with agents targeting PD-1/PD-L1 and CTLA-4 pathways, VEGF signaling, and multikinase inhibition, but these operate through established mechanisms rather than metabolic checkpoint modulation. This absence of direct competitors at the target level gives Pilatus a first-mover position, though it also means the clinical validation of CD36 blockade in humans rests entirely on this program. Whether the metabolic checkpoint approach can translate preclinical activity into measurable patient benefit, either as monotherapy or in combination with atezolizumab, will depend on the dose-escalation data and biomarker readouts from this trial.

---

Spot something wrong? Report an issue with this article